EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL ...

EQL Pharma AB ( (SE:EQL)) has provided an update. EQL Pharma AB has received marketing approval in Germany for its key product, methenamine hippurate, branded as Cystohipp, which will be launched in ...

Cipla introduces HUENA, a non-antibiotic treatment for recurrent urinary tract infections (UTIs) in India. Reduces antibiotic reliance and resistance. New Delhi, Sep 5 (PTI) Drug firm Cipla on Friday ...

Introduction Recurrent urinary tract infections (rUTIs) are typically treated using antibiotics. Given the growing issue of antimicrobial resistance, non-antibiotic management options for rUTIs have ...

Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to manufacture its generic version of Methenamine Hippurate tablets used in treatment of urinary ...

Zydus Lifesciences said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Methenamine Hippurate Tablets. The approved ANDA is a generic ...

Zydus Lifescienceshas received final approval from the United States Food and Drug Administration (USFDA) to manufacture Methenamine Hippurate Tablets USP, 1 gram (USRLD: Hiprex Tablets, 1 gram).

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Methenamine Hippurate Tablets USP, 1 gram (generic version ...

Zydus Lifesciences has received USFDA approval to manufacture its generic version of Methenamine Hippurate tablets for treating urinary tract infections. The drug, manufactured in Ahmedabad, will be ...